Search

Search Constraints

You searched for: Author/Creator Stone, Julie A.

Search Results

4. Immunogenicity of pembrolizumab in patients with advanced tumors. Issue 1 (8th August 2019)

6. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers. (8th April 2013)

7. P1‐038: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE RESULTS FROM EPOCH: A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE. (1st July 2006)

8. P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS. (1st July 2019)

10. P2‐002: AN INTEGRATED MECHANISTIC AMYLOID PATHWAY MODEL INFORMED BY CLINICAL BIOMARKER DATA FROM VERUBECESTAT AND OTHER BACE INHIBITORS. (1st July 2019)